Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.43 |
| ▸ | CERT1 | Q9Y5P4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623032 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL9709528 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623366 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623037 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL10958796 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5821483 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1622513 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5185943 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL557791 | 0.99 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5326495 | 0.99 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744840-B2 | N-palmitoyl-D-glucosamine in a micronized form | INNOVET ITALIA S.R.L. (IT) | 2023-09-05 | — | — | US | claimed |
| US-20210308160-A1 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM | INNOVET ITALIA S.R.L. (IT) | 2021-10-07 | — | — | US | claimed |
| EP-3546469-B1 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM | INNOVET ITALIA SRL (IT) | 2020-11-25 | — | — | EP | claimed |
| EP-3546469-A1 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM | Innovet Italia S.r.l. (IT) | 2019-10-02 | — | — | EP | claimed |
| US-20190290669-A1 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM | INNOVET ITALIA S.R.L. (IT) | 2019-09-26 | — | — | US | claimed |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| US-4323561-A | Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1982-04-06 | — | — | US | claimed |
| US-20260070960-A1 | SINGLE DOMAIN ANTIBODIES TARGETING HPV E6/E7 ONCOGENIC PEPTIDE/MHC COMPLEXES | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-03-12 | — | — | US | disclosed |
| US-12552865-B2 | High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-02-17 | — | — | US | disclosed |
| US-12503695-B2 | RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-12-23 | — | — | US | disclosed |
| US-12492262-B2 | High affinity monoclonal antibodies targeting glypican-2 and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-12-09 | — | — | US | disclosed |
| US-12180296-B2 | Cross species single domain antibodies targeting mesothelin for treating solid tumors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240417446-A1 | SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-19 | — | — | US | disclosed |
| WO-1996018600-A1 | AMIDES OF MONO AND BICARBOXYLIC ACIDS WITH AMINO ACIDS OR GLYCOSAMINES, SELECTIVELY ACTIVE ON THE CANNABINOID PERIPHERAL RECEPTOR | LIFEGROUP S.P.A. (IT) | 1996-06-20 | — | — | WO | disclosed |
| EP-0575517-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES, THE USE THEREOF AS VACCINES AND POLYVALENT HYPERIMMUNE GAMMAGLOBULINS | UNIVAX BIOLOGICS INCORPORATED (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016230-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES, THE USE THEREOF AS VACCINES AND POLYVALENT HYPERIMMUNE GAMMAGLOBULINS | UNIVAX BIOLOGICS INCORPORATED (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1991001750-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES AND THE USE THEREOF AS VACCINES | UNIVAX BIOLOGICS, INC. (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4495346-A | CATALYTICALLY COUPLING TWO MONOSACCHARIDES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1985-01-22 | — | — | US | disclosed |
| US-4323561-A | Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1982-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070960-A1 | SINGLE DOMAIN ANTIBODIES TARGETING HPV E6/E7 ONCOGENIC PEPTIDE/MHC COMPLEXES | MICA, HLA-DRB1, VSIG8 | MEN1 3390/4885KMT2A 2067/4885DEGS1 1014/4885 |
| US-11744840-B2 | N-palmitoyl-D-glucosamine in a micronized form | NAPEPLD, FABP2, FSCN1 | MEN1 2067/4885KMT2A 4438/4885DEGS1 385/4885 |
| US-12552865-B2 | High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors | PDCD1LG2, IGLV6-57, IGSF11 | MEN1 3130/4885KMT2A 15/4885DEGS1 1432/4885 |
| US-20210308160-A1 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM | NAPEPLD, FABP2, FSCN1 | MEN1 2067/4885KMT2A 4438/4885DEGS1 385/4885 |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | MEN1 1658/4885KMT2A 3832/4885DEGS1 640/4885 |
| US-20190290669-A1 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM | NAPEPLD, FABP2, FSCN1 | MEN1 2067/4885KMT2A 4438/4885DEGS1 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.